Literature DB >> 35064309

Review of the holistic management of pediatric atopic dermatitis.

Armaan Guraya1, Karan Pandher2, Caroline L Porter2, Sarah Taylor2, Joseph Jorizzo2, Lindsay Strowd2, Rajesh Balkrishnan3, Steven Feldman2,4,5,6.   

Abstract

Atopic Dermatitis (AD) is a chronic inflammatory skin disease that is broadly characterized by eczematous lesions and pruritus. This condition is detrimental in a multitude of ways, including patient quality of life (QOL), family QOL, economic burden, and psychosocial afflictions. Current management needs to incorporate a holistic approach which considers the financial, emotional, and physical limitations of both the treatments and the provider. A non-systematic search was conducted on the holistic management of pediatric AD. Various search queries were used such as the key terms of "atopic dermatitis," "pediatric," "eczema," "management," and more to encompass treatments, adherence, and comorbidities. There is an association with AD and depression in children, and its prevalence should be screened for routinely in children with AD. Collaboration with other specialties may prove to be prudent in addressing this comorbidity. Objective quality of life scores can open the door to much needed conversation with patients to get them the help they need. In expanding our scope, we find the extended consequences of AD have a ripple effect on families of pediatric patients. Lastly, we introduce a model for improving treatment adherence.
CONCLUSION: Patient quality-of-life can be negatively affected by the symptoms, expense, stigma, and time commitment, and inconvenience imposed by complicated treatment regimens. To ensure proper, holistic management of pediatric AD, multiple factors must be considered; seasonal changes, lifestyle modifications, and the psychosocial impact are just a couple of factors that require monitoring. WHAT IS KNOWN: • Atopic dermatitis impacts patients and their families in quality of life, economically, and psychosocially. • Current treatment revolves largely around treating physical manifestation of disease with first line measures such as topical steroids. WHAT IS NEW: • The holistic management of AD incorporates a good physician-patient relationship, frequent follow-up, and providing structured written plans. • We introduce the house building model for improving treatment adherence. KEY POINTS: Pediatric AD can be managed in a more holistic manner which incorporates several factors from the lives of patients and their families. Pediatric patients suffer from many physical and mental comorbidities which should be screened for. Adherence with treatment may be improved by following a model which emphasizes establishing a good physician-patient relationship, frequent follow-up, and providing structured written plans.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Adherence; Atopic dermatitis; Dermatology; Eczema; Holistic; Medication; Pediatric

Mesh:

Year:  2022        PMID: 35064309     DOI: 10.1007/s00431-021-04341-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  3 in total

1.  An Anchoring-Based Intervention to Increase Patient Willingness to Use Injectable Medication in Psoriasis.

Authors:  Elias Oussedik; Leah A Cardwell; Nupur U Patel; Omobola Onikoyi; Steven R Feldman
Journal:  JAMA Dermatol       Date:  2017-09-01       Impact factor: 10.282

2.  Parental response to written eczema action plans in children with eczema.

Authors:  Jillian F Rork; William J Sheehan; Jonathan M Gaffin; Karol G Timmons; Robert Sidbury; Linda C Schneider; Wanda Phipatanakul
Journal:  Arch Dermatol       Date:  2012-03

3.  Association between atopic dermatitis, depression, and suicidal ideation: A systematic review and meta-analysis.

Authors:  Kevin R Patel; Supriya Immaneni; Vivek Singam; Supriya Rastogi; Jonathan I Silverberg
Journal:  J Am Acad Dermatol       Date:  2018-10-23       Impact factor: 11.527

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.